The Human rotavirus vaccine market overview and analysis by type, by end users- forecast till 2030. Rotavirus vaccine is used to protect against rotavirus infections which cause severe diarrhoea among young children. Rotavirus vaccine is administered by mouth and requires two or three doses which are given starting around six weeks of age. In the United States, the vaccination first became accessible in 2006. A double-stranded RNA virus belonging to the Reoviridae family, rotavirus spreads orally through faeces. It causes gastroenteritis by infecting the small intestine's cell lining. The National Center for Biotechnology Information estimates that rotavirus-related diarrhoea kills over 600,000 children each year, with more than 80% of these deaths taking place in south Asia and sub-Saharan Africa.
Almost 5% of all deaths in children under the age of five globally are thought to be caused by rotavirus. By the time they turn five, almost every child in the globe has contracted the rotavirus at least once. The inclusion of the rotavirus vaccine in national routine vaccination regimens is advised by the World Health Organization (WHO). In the underdeveloped world, the immunisations are responsible for preventing 15 to 34% of severe diarrhoea, while in the affluent world, 37 to 96%. The use of the vaccine, according to the World Health Organization (WHO), has directly contributed to a reduction of up to 50% in diarrheal fatalities in children under the age of five in Mexico.
The most appealing strategy for the human rotavirus vaccine industry is product development. Due to the fact that the first rotavirus vaccine, RotaShield, caused intussusception as a side effect, more recent vaccinations have withstood historical safety profiles. Although human rotavirus vaccines are significantly more expensive per dose than the least expensive conventional therapy, cost-effective manufacture continues to be a problem.
Global Human Rotavirus Vaccine Market Players
Key players profiled in the report are Bharat Biotech, Merck Co., Inc., GlaxoSmithKline plc, Sanofi and others.
The global Human rotavirus vaccine market size has been segmented on the basis of type and end users.
Based on type, the market has been segmented as Rotarix, RotaTeq, Rotavac, Rotavin-M1, Lanzhou lamb and others.
Based on the end users, the market has been segmented as hospitals clinics, academic and research and others.
The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new technology in the US drives the global human rotavirus vaccine market. Also, concentration of major research companies and vaccine research sector in the developed countries of this region is adding fuel to the market growth.
Europe is the second largest market in the world due to high income and healthcare penetration.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: [email protected]